Clinical trial
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers
NCT05090111 is registered in ClinicalTrials.gov with Aligos Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers
- Lead sponsor
- Aligos Therapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 1, 2021
- Completion date
- June 16, 2023
- Enrollment
- 98 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
nash - nonalcoholic steatohepatitis